SLU-PP-332 Dosing: Research Protocols and What the Evidence Shows (2026)
Key Takeaways
- SLU-PP-332 is not FDA-approved and has no human clinical trials. Every published study is in cell cultures or rodents.
- It is an estrogen-related receptor (ERR) agonist — not a PPARδ agonist, as some sources incorrectly state — that mimics aspects of aerobic exercise at the cellular level.[1]
- Animal studies use weight-based doses (mg/kg) that cannot be directly converted to human doses.
- Community protocols circulating online cluster around 500–700 mcg per day, but these have no controlled-trial basis.
- Nothing on this page is a recommendation to use SLU-PP-332. It is a research compound with an unknown human safety profile.
What Is SLU-PP-332?
SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ. These receptors regulate mitochondrial function, fatty acid oxidation, and oxidative metabolism — the same pathways activated by endurance exercise. For that reason SLU-PP-332 is described in the literature as an exercise mimetic: in rodent models it produces some of the metabolic adaptations of aerobic training without the animal exercising.[1]
It is important to be precise about what SLU-PP-332 is not. It is frequently mislabeled as a PPARδ agonist (the class that includes cardarine/GW501516). The published pharmacology shows it acts through the estrogen-related receptors, a distinct target.[1][2] It is also not a peptide — it is a synthetic small molecule — though it is sold and discussed alongside research peptides.
What the Research Actually Shows
Every verified study on SLU-PP-332 is preclinical. There are no human trials, registered or published.
| Study | Model | Finding |
|---|---|---|
| ERR agonist alleviates metabolic syndrome (2024)[1] | Mouse | Improved metabolic parameters in a metabolic-syndrome model |
| Synthetic ERRα/β/γ agonist enhances exercise capacity (2023)[2] | Mouse | ERRα-dependent acute aerobic exercise response |
| Pan-ERR agonists ameliorate heart failure (2024)[3] | Animal | Enhanced cardiac fatty-acid metabolism and mitochondrial function |
| ERR agonism reverses mitochondrial dysfunction (2023)[4] | Animal (kidney) | Reduced mitochondrial dysfunction and inflammation in aging |
These are mechanistic and proof-of-concept findings in animals. They establish that the compound is biologically active at its target — they do not establish a safe or effective human dose.
Dosing: What Exists and What Doesn't
There is no established human dose
No clinical trial has administered SLU-PP-332 to humans. There is no FDA label, no prescribing information, and no peer-reviewed human pharmacokinetic data. Any specific human dose presented anywhere — including the community figures below — is extrapolation, not evidence.
Animal-study doses
Published rodent studies use weight-based dosing (mg/kg). These figures are reported for scientific transparency and cannot be scaled to humans by simple arithmetic; interspecies scaling requires allometric conversion and pharmacokinetic data that do not yet exist for this compound.
Circulating community protocols
Despite the absence of human data, dosing protocols circulate on peptide and research-chemical websites. Aggregating across multiple independent sources, the commonly cited community range clusters around:
| Parameter | Circulating practice | Basis |
|---|---|---|
| Daily amount | ~500–700 mcg/day | Community consensus across ~9 independent sites |
| Starting approach | ~250 mcg/day, titrated up | Community practice, not trial data |
| Frequency | Once daily | Community practice |
| Route | Oral (most common), some subcutaneous | Community practice |
This range reflects what is discussed in the research-chemical community, not what any study has validated. We report it because people searching for SLU-PP-332 dosing will encounter these figures, and it is more honest to present them with their actual provenance than to dress them up as clinical guidance. They carry no safety guarantee.
What the Evidence Does Not Show
Being direct about the gaps matters more than the numbers:
- No human safety data. Acute and chronic toxicity in humans is unknown.
- No human efficacy data. The exercise-mimetic effect is demonstrated in rodents only.
- No established dose-response in humans. The community range is convention, not pharmacology.
- No long-term data. Chronic ERR agonism effects over months or years are unstudied in any species at human-equivalent exposure.
- Doping relevance. SLU-PP-332 and its metabolites have been characterized specifically for doping-control purposes, indicating anti-doping interest in detecting it.[5]
